Keros Therapeutics downgraded by Wedbush with a new price target
$KROS
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/10/2025 | $18.00 | Buy → Neutral | BofA Securities |
| 1/21/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 1/17/2025 | $15.00 | Outperform → Neutral | Wedbush |
| 12/16/2024 | $102.00 → $63.00 | Outperform | Oppenheimer |
| 12/16/2024 | Buy → Neutral | Guggenheim | |
| 12/13/2024 | $100.00 → $47.00 | Buy | H.C. Wainwright |
| 12/12/2024 | Buy → Hold | TD Cowen | |
| 12/12/2024 | Outperform → Mkt Perform | William Blair |